Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma

Kyoichi Kaira; Osamu Kawashima; Hedeki Endoh; Kazuyoshi Imaizumi; Yasuhiro Goto; Mitsuhiro Kamiyoshihara; Masayuki Sugano; Ryohei Yamamoto; Takashi Osaki; Shigefumi Tanaka; Atsushi Fujita; Hisao Imai; Yoshihito Kogure; Yukio Seki; Kimihiro Shimizu; Akira Mogi; Yoshinori Shitara; Tetsunari Oyama; Yoshikatsu Kanai; Takayuki Asao

doi:10.1016/j.humpath.2018.09.020

Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma

Kyoichi Kaira, Osamu Kawashima, Hedeki Endoh, Kazuyoshi Imaizumi, Yasuhiro Goto, Mitsuhiro Kamiyoshihara, Masayuki Sugano, Ryohei Yamamoto, Takashi Osaki, Shigefumi Tanaka, Atsushi Fujita, Hisao Imai, Yoshihito Kogure, Yukio Seki, Kimihiro Shimizu, Akira Mogi, Yoshinori Shitara, Tetsunari Oyama, Yoshikatsu Kanai, Takayuki Asao

Respiratory Medicine & Clinical Allergy

Research output: Contribution to journal › Article

10 Citations (Scopus)

Abstract

Amino acid transporters are necessary for tumor growth, metastasis, and survival of various neoplasms; however, the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and 4F2 cell surface antigen (4F2hc) in patients with pulmonary pleomorphic carcinoma (PPC) remainsunknown. The aim of this study is to clarify the prognostic impact of these amino acid transporters in PPC. One hundred five patients with surgically resected PPC were assessed by immunohistochemistry. The expression of LAT1 and 4F2hc, and Ki-67 labeling index were investigated using specimens of the resected tumors. LAT1 and 4F2hc were highly expressed in 35% and 53% of all patients (n = 105, P <.01), 25% and 48% of patients with an adenocarcinoma component (n = 48, P =.02), and 44% and 58% of patients with a nonadenocarcinoma component (n = 57, P =.18), respectively. A high LAT1 expression was significantly related to advanced disease, lymphatic permeation, tumor cell proliferation, and 4F2hc expression. By multivariate analysis, LAT1 and 4F2hc were identified as significant independent markers for predicting a worse prognosis. LAT1 is highly expressed in PPC, and high LAT1 expression can serve as a significant predictor linked to a worse prognosis in patients with PPC.

Original language	English
Pages (from-to)	142-149
Number of pages	8
Journal	Human Pathology
Volume	84
DOIs	https://doi.org/10.1016/j.humpath.2018.09.020
Publication status	Published - 02-2019

All Science Journal Classification (ASJC) codes

Pathology and Forensic Medicine

Access to Document

10.1016/j.humpath.2018.09.020

Fingerprint Dive into the research topics of 'Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma'. Together they form a unique fingerprint.

Cite this

Kaira, K., Kawashima, O., Endoh, H., Imaizumi, K., Goto, Y., Kamiyoshihara, M., Sugano, M., Yamamoto, R., Osaki, T., Tanaka, S., Fujita, A., Imai, H., Kogure, Y., Seki, Y., Shimizu, K., Mogi, A., Shitara, Y., Oyama, T., Kanai, Y., & Asao, T. (2019). Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Human Pathology, 84, 142-149. https://doi.org/10.1016/j.humpath.2018.09.020

Kaira, Kyoichi ; Kawashima, Osamu ; Endoh, Hedeki ; Imaizumi, Kazuyoshi ; Goto, Yasuhiro ; Kamiyoshihara, Mitsuhiro ; Sugano, Masayuki ; Yamamoto, Ryohei ; Osaki, Takashi ; Tanaka, Shigefumi ; Fujita, Atsushi ; Imai, Hisao ; Kogure, Yoshihito ; Seki, Yukio ; Shimizu, Kimihiro ; Mogi, Akira ; Shitara, Yoshinori ; Oyama, Tetsunari ; Kanai, Yoshikatsu ; Asao, Takayuki. / Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. In: Human Pathology. 2019 ; Vol. 84. pp. 142-149.

@article{04e8784128304a55aa253ead1603c0eb,

title = "Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma",

abstract = "Amino acid transporters are necessary for tumor growth, metastasis, and survival of various neoplasms; however, the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and 4F2 cell surface antigen (4F2hc) in patients with pulmonary pleomorphic carcinoma (PPC) remainsunknown. The aim of this study is to clarify the prognostic impact of these amino acid transporters in PPC. One hundred five patients with surgically resected PPC were assessed by immunohistochemistry. The expression of LAT1 and 4F2hc, and Ki-67 labeling index were investigated using specimens of the resected tumors. LAT1 and 4F2hc were highly expressed in 35% and 53% of all patients (n = 105, P <.01), 25% and 48% of patients with an adenocarcinoma component (n = 48, P =.02), and 44% and 58% of patients with a nonadenocarcinoma component (n = 57, P =.18), respectively. A high LAT1 expression was significantly related to advanced disease, lymphatic permeation, tumor cell proliferation, and 4F2hc expression. By multivariate analysis, LAT1 and 4F2hc were identified as significant independent markers for predicting a worse prognosis. LAT1 is highly expressed in PPC, and high LAT1 expression can serve as a significant predictor linked to a worse prognosis in patients with PPC.",

author = "Kyoichi Kaira and Osamu Kawashima and Hedeki Endoh and Kazuyoshi Imaizumi and Yasuhiro Goto and Mitsuhiro Kamiyoshihara and Masayuki Sugano and Ryohei Yamamoto and Takashi Osaki and Shigefumi Tanaka and Atsushi Fujita and Hisao Imai and Yoshihito Kogure and Yukio Seki and Kimihiro Shimizu and Akira Mogi and Yoshinori Shitara and Tetsunari Oyama and Yoshikatsu Kanai and Takayuki Asao",

year = "2019",

month = feb,

doi = "10.1016/j.humpath.2018.09.020",

language = "English",

volume = "84",

pages = "142--149",

journal = "Human Pathology",

issn = "0046-8177",

publisher = "W.B. Saunders Ltd",

}

Kaira, K, Kawashima, O, Endoh, H, Imaizumi, K , Goto, Y, Kamiyoshihara, M, Sugano, M, Yamamoto, R, Osaki, T, Tanaka, S, Fujita, A, Imai, H, Kogure, Y, Seki, Y, Shimizu, K, Mogi, A, Shitara, Y, Oyama, T, Kanai, Y & Asao, T 2019, 'Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma', Human Pathology, vol. 84, pp. 142-149. https://doi.org/10.1016/j.humpath.2018.09.020

Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. / Kaira, Kyoichi; Kawashima, Osamu; Endoh, Hedeki; Imaizumi, Kazuyoshi ; Goto, Yasuhiro; Kamiyoshihara, Mitsuhiro; Sugano, Masayuki; Yamamoto, Ryohei; Osaki, Takashi; Tanaka, Shigefumi; Fujita, Atsushi; Imai, Hisao; Kogure, Yoshihito; Seki, Yukio; Shimizu, Kimihiro; Mogi, Akira; Shitara, Yoshinori; Oyama, Tetsunari; Kanai, Yoshikatsu; Asao, Takayuki.

In: Human Pathology, Vol. 84, 02.2019, p. 142-149.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma

AU - Kaira, Kyoichi

AU - Kawashima, Osamu

AU - Endoh, Hedeki

AU - Imaizumi, Kazuyoshi

AU - Goto, Yasuhiro

AU - Kamiyoshihara, Mitsuhiro

AU - Sugano, Masayuki

AU - Yamamoto, Ryohei

AU - Osaki, Takashi

AU - Tanaka, Shigefumi

AU - Fujita, Atsushi

AU - Imai, Hisao

AU - Kogure, Yoshihito

AU - Seki, Yukio

AU - Shimizu, Kimihiro

AU - Mogi, Akira

AU - Shitara, Yoshinori

AU - Oyama, Tetsunari

AU - Kanai, Yoshikatsu

AU - Asao, Takayuki

PY - 2019/2

Y1 - 2019/2

N2 - Amino acid transporters are necessary for tumor growth, metastasis, and survival of various neoplasms; however, the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and 4F2 cell surface antigen (4F2hc) in patients with pulmonary pleomorphic carcinoma (PPC) remainsunknown. The aim of this study is to clarify the prognostic impact of these amino acid transporters in PPC. One hundred five patients with surgically resected PPC were assessed by immunohistochemistry. The expression of LAT1 and 4F2hc, and Ki-67 labeling index were investigated using specimens of the resected tumors. LAT1 and 4F2hc were highly expressed in 35% and 53% of all patients (n = 105, P <.01), 25% and 48% of patients with an adenocarcinoma component (n = 48, P =.02), and 44% and 58% of patients with a nonadenocarcinoma component (n = 57, P =.18), respectively. A high LAT1 expression was significantly related to advanced disease, lymphatic permeation, tumor cell proliferation, and 4F2hc expression. By multivariate analysis, LAT1 and 4F2hc were identified as significant independent markers for predicting a worse prognosis. LAT1 is highly expressed in PPC, and high LAT1 expression can serve as a significant predictor linked to a worse prognosis in patients with PPC.

AB - Amino acid transporters are necessary for tumor growth, metastasis, and survival of various neoplasms; however, the clinicopathological significance of L-type amino acid transporter 1 (LAT1) and 4F2 cell surface antigen (4F2hc) in patients with pulmonary pleomorphic carcinoma (PPC) remainsunknown. The aim of this study is to clarify the prognostic impact of these amino acid transporters in PPC. One hundred five patients with surgically resected PPC were assessed by immunohistochemistry. The expression of LAT1 and 4F2hc, and Ki-67 labeling index were investigated using specimens of the resected tumors. LAT1 and 4F2hc were highly expressed in 35% and 53% of all patients (n = 105, P <.01), 25% and 48% of patients with an adenocarcinoma component (n = 48, P =.02), and 44% and 58% of patients with a nonadenocarcinoma component (n = 57, P =.18), respectively. A high LAT1 expression was significantly related to advanced disease, lymphatic permeation, tumor cell proliferation, and 4F2hc expression. By multivariate analysis, LAT1 and 4F2hc were identified as significant independent markers for predicting a worse prognosis. LAT1 is highly expressed in PPC, and high LAT1 expression can serve as a significant predictor linked to a worse prognosis in patients with PPC.

UR - http://www.scopus.com/inward/record.url?scp=85059858167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059858167&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2018.09.020

DO - 10.1016/j.humpath.2018.09.020

M3 - Article

C2 - 30300664

AN - SCOPUS:85059858167

VL - 84

SP - 142

EP - 149

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -